Introduction
Photodynamic therapy (PDT) is a relatively new modality of cancer treatment. Actual ongoing clinical era started with the studies of Dougherty in the 1970s. PDT is based on the application of a so called photosensitizer (PS), which preferably enriches in the tumor tissue. The application of light at an appropriate wavelength excites the PS molecules from their ground state S 0 to an electronically excited singlet state S x . The energy of the excited state can be dissipated via several relaxation pathways. By this, so called cytotoxic reactive oxygen species (ROS) are generated. ROS react with various biomolecules inducing cell death by different mechanims. (Dougherty et al. 1998b) 
History of PDT
The newer history of PDT starts with the observations of Von Tappeiner and Raab at the Maximilian Ludwig University in Munich. In 1900, Raab first reported on the chemical sensitisation of tissue by light. (Raab 1900) Von Tappeiner described in 1904 the so called "photodynamic reaction". (Tappeiner & Jodlbauer 1904) He believed that this effect was based on fluorescence. In contrast Neiser (Breslau) and Dreyer (Finsen Institue in Kopenhagen) described a sensitisation by light for photodynamic reaction. (Dreyer 1903; Neisser & Halberstaedtter 1904) At this time Ledoux-Lebards already proved the concept of the presence of oxygen as a condition for PDT at the Institute Pasteur in Paris (1902) . (Ledoux-Lebards 1902) In this era skin diseases were treated with chinidin, acridin and eosin with unsatisfying results. Already from the beginning of PDT, haematoporphyrin (Hp) was of special interest. Hausmann used Hp for photodynamic investigations in mice in 1911. (Hausmann 1911) In 1913, Meyer-Betz studied Hp to determine its biological effects on himself. After exposition to sunlight he suffered from extensive phototoxic reactions. (Meyer-Betz 1913) Policard detected 1924 in rat sarcoma a red fluorescence after Hp administration. (Policard 1924) In 1942 Auler and Banzer reported on the affinity of neoplastic tissues for Hp in tumor, metastases and lymphatic vessels in patients suffering cancer. (Auler & Banzer 1942) Further investigations were performed by Figge et al. in 1948 ; they demonstrated the properties of Hp to localize tumors. (Figge, Weiland, & Manganiello 1948) Due to high toxic reactions of Hp, in 1955 a hematoporphyrin derivat (HpD) was developed by Schwartz et al.. (Schwartz, Absolon, & Vermund 1955) This derivat also contained many components of hematoporphyrins. Lipson et al. used the HpD in vivo and in patients for tumor detection and localisation in the early sixties. (Lipson, Baldes, & Olsen 1964) A milestone in PDT was done by Dougherty in 1973 .(Dougherty 1973 ) Dougherty postulated the criteria for PSs and for PDT. Essential for a successful PS is less or no toxicity without light, selective enrichment in the tumor or affected tissue and activation by light with a wavelength of 600 nm or more. (Dougherty et al. 1978; Dougherty et al. 1998a ) HpD was further purified by Dougherty's group to Photofrin ® . Photofrin is up to now for PDT drug approved.
First and second generation photosensitizers
HpD and Photofrin ® are first generation PSs. The maximum of absorption of HpD is 628 to 632 nm. Penetration depth is about 5 mm. In vivo the concentration of HpD is twelve times higher compared to normal brain tissue. In clinical investigations the concentration was 1:2.5 to 1:4 fold. (Kostron, Obwegeser, & Jakober 1996) This first generation PSs have some disadvantages, e.g. high impurity, prolonged skin photosensitivity about several weeks and low absorbance at 630 nm, where tissue penetration of light is low. To improve this, second generation photosensitizers (phthalocyanines, naphthalocyanins, benzoporphyrins, chlorines, purpurins, texaphyrins, porphycenes, pheophobides, bacteriochlorins, etc.) were introduced (Juzeniene, Peng, & Moan 2007) . Second generation PSs have a high absorbance in the region of 650-850 nm and produce adequate singlet oxygen. Meta-tetra hydroxyphenylchlorin (m-THPC; Foscan ® , Biolitec AG) and benzoporphyrin derivative monoacid A (BPD-MA; Visudyne ® , QLT Inc. and Novartis Opthalmics) are approved drugs for clinical use. The second generation PS mTHPC has its maximum absorption at 652 nm. Phototoxic reaction had been observed up to a depth of 15 mm. For metatetrahydroxyphenylchlorin (mTHPC) a ratio tumor to normal tissue of more than 80:1 has been described in vivo after implantation of C6 glioma in Spraque-Dawley rats. In clinical applications the ratio tumor to normal brain tissue was 20:1. (Dougherty, Gomer, Henderson, Jori, Kessel, Korbelik, Moan, & Peng 1998a; Obwegeser, Jakober, & Kostron 1998 ) Several more PSs are available, but have been less usage in neurosurgery. Third generation PSs are second generation photosensitizers bound to carriers for selective accumulation in the tumor. visualisation. (Stummer et al. 2000; Stummer et al. 2006; Stummer et al. 2008 ) 5-ALA is a precursor, converted in malignant cells to PpIX, the fluorescent substance. 5-ALA is the first substrate in the heme biosynthesis. Heme biosynthesis consists of eight discrete enzymes catalysed steps which involve the mitochondrial (the first and the last three steps) and cytosolic (the other four intermediate steps) compartments of the cell. In the first step 5-ALA is produced by ALA synthetase in the mitochondria. This is the rate-limiting step in heme biosynthesis. 5-ALA is actively transported to the cytoplasm. After reentry into the mitochondrion, PpIX is produced. PpIX is the last step in the heme pathway before forming heme by insertion of ferrous iron by the enzyme ferrochelatase. Mitochondrial ferrochelatase is dependent on mitochondrial energy generation. In malignant tissue ferrochelatase is reduced, therefore PpIX, a strongly fluorescent and effective tissue PS accumulates in higher concentrations after application of 5-ALA in gliomas. (Kemmner et al. 2008 
Prodrug

Photodiagnosis and photodynamic therapy in neurosurgery
Currently, standard treatment of glioblastoma is based on microsurgical tumour resection, radiation and chemotherapy. Overall prognosis of glioblastoma patients remains poor; therefore, new therapeutical options are necessary. Glioblastomas are diffuse infiltrating tumors, with growth patterns according to Scherer as follows: (i)perineuronal growth (perineuronal satellitosis); (ii) surface (subpial) growth; (iii) perivascular growth and (iv) intrafascicular growth. (Peiffer & Kleihues 1999) Due to the fact that tumor recurrence occurs most frequently at the resection margins, PDT of malignant glioma might be a promising treatment option as a local therapy. Additionally PDT might be able to reach the so called Guerilla cells (Claes, Idema, & Wesseling 2007) , tumor cells localized in the brain adjacent to tumor region (BAT region) by local therapy at the end of the resection and perhaps by PDT stimulated anti-tumor immunity. Stimulation o f a n t i -t u m o r i m m u n i t y b y P D T i s o f f increasing relevance, an opportunity for PDT to become quite more than another local glioma treatment method. This topic will be discussed later in the chapter. In the 1970s, when lasers and optical light delivery systems became available, the therapeutic use of Hp maintained interest also in neurosurgery. 
Photodiagnosis (PD) and PDT with 5-ALA PpIX
Introduction of 5-ALA fluorescence guided resection was a milestone in neurosurgery in the last fifteen years. Great contribution was done by Stummer and coworkers. 5-ALA is orally applied about 4 hours before surgery. Surgery is performed under operating microscope, during resection the surgeon is able to switch between the white light mode and the fluorescent mode (blue light), where the tumour appears red fluorescent, see also figure 1. The first results of improvement of the radicality of resection by 5-ALA fluorescence guided surgery were published in the nineties. The results of a randomised controlled multicentre phase III trial performed are summerized. The German study group investigated 322 patients enrolled by 32 investigators at 17 study centres. 161 patients were treated by fluorescence-guided surgery with 5-ALA, (20 mg/kg bodyweight; medac, Wedel, Germany), 161 were resected under conventional white light mode. In the fluorescence guided resection group tumor was resected completely in 65%, in the white light group complete tumor resection was achieved only in 36% of patients, as investigated by early postsurgical MRI. The difference between the groups was 29% [95% Confidence interval (CI) 17-40], p<0.0001. Stummer et al. 2006 Stratification by postoperative MRI findings showed that patients without residual contrastenhancing tumor had higher overall median survival than did those with residualenhancing tumour (17.9 months 
PDT in neurosurosurgery clinical studies -an overview
Currently Kostron (2010) 
Hypericin -high potential for PD and PDT
Hypericin, a Naphtodianthron is a naturally occurring compound of the plant Hypericum perforatum, better known as St. John's wort. St. John's wort is a plant that has been used since the Middle Ages to treat wounds and depression. It grows bushy and has its peak season between May and August, see figure 2. St. John's wort contains the following active ingredients: essential oils, flavonoids (Biapigenin, hyperoside, Isoquercitin, rutin), tannins, glycosides, resins, Naphtodianthrone (hypericin, Pseudohyericin) and phloroglucinol (hyperforin). In 1942 by Pace a pronounced sensitization of the skin by light for grazing animals taken St. John's wort containing feed was described. The changes in the skin were reversible after the animals were protected from sun exposure. The phenomenon was described as hypericism. (Pace 1942) Hypericin is a lipophilic molecule that is incorporated into the phospholipid bilayer of cell membranes and has already in the dark versatile pharmacological activities. These include antiviral, anticancer and antiangiogenic properties. Takahashi et al. could show an inhibitory effect on proteinkinase C, which is involved in cell proliferation. (Takahashi et al., 1989) Malignant gliomas have, compared to glial cells, a high proteinkinase C activity. (Couldwell et al. 1991 ) Hypericin has excellent properties as a PS. It has a high triplet quantum yield and a high efficiency in the formation of ROS. (Diwu & Lown 1993; Ehrenberg, Anderson, & Foote 1998; Hadjur et al. 1996) The excessive production of the so called ROS leads to oxidative stress to many biomolecules, e.g. proteins, causing cell death by induction of apoptosis, necrosis or autophagy associated cell death. www.intechopen.com
Hypericin differentiating neurons and glioma cell lines in vitro
For selective PDT it would be advantageous when the PS enriches in the malignant cells more compared to neurons or glial cells. In 2005 we investigated eight human glioma cell lines (L; LN-18,LN-229, U87MG, U373MG, D247MG, U251MG, U251MG,T98G) and twelve primary human glioma cell cultures (P) and compared the hypericin uptake with human astrocytes (AC; SV-FHAS) and cerebellar granule neurons (N) prepared from 8-day-old Sprague-Dawley rat pups (Charles River, Sulzfeld, Germany). Long term glioma cell lines and primary human glioma cell cultures showed significant higher hypericin uptake compared to neurons. Hypericin uptake in astrocytes was higher compared to glioma cells and to neurons. (Ritz et al. 2005) Another investigation done by fluorescence microscopy showed that hypericin was predominately localized in the glial envelope surrounding the neuron in a model with crayfish neuron and surrounding glia. Uzdensky et al. found a minor fraction of hypericin in the neuron compared to the glia in this model. (Uzdensky et al. 2003) 
Subcellular distribution of hypericin
Predominantly perinuclear localization of hypericinis is in common concordance. (Uzdensky et al. 2001 ) The more detailed description of subcellular distribution of hypericin is not uniform. Due to the very short life span of the singlet-oxygen for cytotoxic reactions, the subcellular distribution of hypericin is off interest to understand PDT mechanisms in more detail. Many investigators studied in different cultured cell lines with different methods the subcellular hypericin localisation. According to our studies hypericin enriches particularly in the endoplasmatic reticulum (ER) and the Golgi apparatus (GA) in U37MG glioblastoma cells after incubation with noncytotoxic hypericin (1µM, 2h incubation time). ER is predominantly found in the perinuclear region while the GA is more distant to the nucleus, see figure 3 . (Ritz et al. 2007b; Ritz et al. 2008 ) Fig. 3a . Long-term glioblastoma, incubated with 20µM Hypericin. Note the perinuclear granular enrichment.
www.intechopen.com 
Kinetic of intracellular accumulation of hypericin
The cellular accumulation of hypericin in glioma cell culture is time and concentration dependent. Short incubation times of 2 h lead to saturation up to 5µM hypericin, higher concentrations do not increase hypericin accumulation. Cellular hypericin uptake is subjected by active temperature dependent transport mechanism, although details are not clear at all (Fig. 4) . ( 1.5 µM (♦) and 2.5 µM (▲). Illumination was performed at 595 nm, light was delivered at 5-10 mW/cm 2 . Cell viability is given on the ordinate.
Tumor selectivity of hypericin in vivo
Basical for a successful clinical application of hypericin for fluorescence guided resection and PDT is a selective enrichment in tumor tissue without enrichment in normal brain tissue. For this we evaluated in a C6 rat glioma model selective hypericin accumulation in tumor tissue compared to BAT zone and normal brain tissue. By these experiments it could be demonstrated that ratios of hypericin in rat glioma compared to BAT and normal brain tissue were 19.8:2.5:1 (Fig. 6) . (Noell et al. 2011) Hypericin was found in a high concentration in tumor tissue, BAT zone was also enriched by hypericin in contrast to normal brain tissue were no hypericin was found.
Our first clinical results demonstrated also a high potential of hypericin for fluorescence guided surgery in malignant glioma, data are submitted for publication. 
Photodynamic therapy and anti-tumor immunity -A chance for PDT to be more than a local cancer therapy?
In malignant brain tumors standard therapy is based on surgery, radiation and chemotherapy. The prognosis of patients is still dismal. There is no doubt about the necessitiy of other treatment options. As mentioned in this chapter PDT represents an interesting therapy option in addition to the modern therapeutical strategies described in this book. At the first moment PDT seems only as one additional tool of local tumor treatment, with all advantages, e.g. low costs compared to modern biotechnical products, selective and repetitive application. Therapy resistancy has been seldom observed. PDT is able to occluse tumor associated vessels, mainly PDT induces apoptosis and necrosis, also autophagy plays a role. Great hope lies in the modulation of immune system by PDT. Fluorescence guided tumor resection is able to eradicate tumor locally. In combination with induced systemic anti-tumor immune reactions distant tumor cells, e.g. Guerilla cells could be treated. Several mechanisms contribute therefore. Cells killed by PDT produce signals, increasing antigen presentation by dendric cells (DCs) and recruit antigen-specific cytotoxic T lymphocytes (CTLs). (Mroz et al. 2011) Great importance is also given to so called damage-associated molecular patterns (DAMPs). DAMPs are intracellular molecules in living cells, exposed by sudden cell damage as initialized for example by PDT. Up to date it is generally accepted that PDT activates the immune system. Complete understanding of the processes and how to influence them for improvement the immune responses is mandatory and could be advanced by closer cooperation of researchers in PDT and immunology.
Conclusion and future directions
PDT for malignant gliomas is an interesting additional therapeutic tool with low side effects. By fundamentally distinct mechanisms compared to radiochemotherapy PDT also offers new opportunities for patients with tumor relapse. Hypericin seems to be a quite effective fluorescence marker for the detection of glioma. Since hypericin exhibits excellent photosensitizing properties, as demenostrated in detail in vitro, it might also be a promising PS in glioma therapy. Further in vivo investigations will proof this hypothesis in future. Due to high induction of apoptosis by hypericin mediated PDT, further investigations should focus on anti-tumor immunity by hypericin PDT, a chance to be more than only a local therapeutic tool.
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